We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Three Times Daily Dosing of UT-15C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01746485
Recruitment Status : Completed
First Posted : December 11, 2012
Last Update Posted : December 12, 2012
Information provided by (Responsible Party):
United Therapeutics

August 16, 2012
December 11, 2012
December 12, 2012
July 2012
July 2012   (Final data collection date for primary outcome measure)
Area under the curve (AUC) from 0-24hrs after 6 days of TID dosing. [ Time Frame: 6 days ]
Cmax, tmax, AUC(0-6), AUC(0-24), AUC(6-12), AUC(12-24) and t1/2
Steady-state pharmacokinetics following repeat doses of 0.5mg UT-15C three times daily [ Time Frame: 6 days ]
Cmax, tmax, AUC(0-6), AUC(0-24), AUC(6-12), AUC(12-24) and t1/2
Complete list of historical versions of study NCT01746485 on ClinicalTrials.gov Archive Site
PK profile of UT-15C after a single 0.5mg dose on Day 1 [ Time Frame: 1 day ]
Day 1: Cmax, tmax, AUC(0-6), AUC(0-24), AUC(0-t), AUC(0-inf), and t1/2
Same as current
Not Provided
Not Provided
Three Times Daily Dosing of UT-15C
A PK Evaluation of Three Times Daily Dosing of UT-15C SR Tablets in Healthy Subjects
To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers
Not Provided
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Drug: UT-15C
Other Names:
  • treprostinil diethanolamine
  • treprostinil diolamine
  • UT-15C SR
Experimental: UT-15C
Intervention: Drug: UT-15C
Jones A, Wang-Smith L, Pham T, Laliberte K. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. J Cardiovasc Pharmacol. 2014 Mar;63(3):227-32. doi: 10.1097/FJC.0000000000000039.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2012
July 2012   (Final data collection date for primary outcome measure)
  • Healthy male and female subjects
  • aged 18-55 years of age;
  • weight between 50 and 100 kg, with a body mass index (BMI) between 19.0 and 29.9 kg/m2, inclusive for female subjects and
  • weight between 50 and 120 kg, with a BMI between 19.0 and 32.0 kg/m², inclusive for male subjects.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
United Therapeutics
United Therapeutics
Not Provided
Principal Investigator: Theresa Pham, MD PPD
United Therapeutics
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP